Description
Rubraca (rucaparib) is an orally administered medication belonging to the class of PARP inhibitors. It is used to treat patients with advanced ovarian cancer and prostate cancer.
Uses:
Rubraca is approved for the treatment of platinum-sensitive recurrence in patients with advanced ovarian cancer and germline or somatic BRCA mutations. It is also approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation or a deleterious ATM mutation.
Storage conditions:
Rubraca should be stored at room temperature, between 20-25°C (68-77°F). It should be stored away from light and moisture, and in a closed container.
Mechanism of action:
Rubraca works by inhibiting an enzyme called PARP (poly (ADP-ribose) polymerase), which is involved in DNA repair processes. This leads to the accumulation of DNA damage in cells that have already been damaged by chemotherapy, leading to cell death.
HOW TO USE:
Rubraca is an orally administered medication, taken with or without food. The dosage and duration of treatment may vary depending on the patient’s condition. Patients should follow their doctor’s instructions carefully regarding the use of Rubraca.
Precautions:
Rubraca may cause an increased risk of developing a second cancer. Patients should inform their healthcare provider of any history of cancer before taking the medication. Rubraca may also cause bone marrow suppression, which can increase the risk of infections. Patients should inform their healthcare provider of any symptoms of infection, such as fever, cough, and sore throat.
Drug Interactions:
Rubraca may interact with other medications, particularly those that affect liver enzymes, such as CYP2D6 and CYP3A4. Patients taking any medications that may affect liver enzyme levels should inform their healthcare provider before taking Rubraca.
Contraindications:
Rubraca is contraindicated in patients with severe hypersensitivity to rucaparib or any of its components. It should not be used in pregnant women, as it may cause harm to the developing fetus.
Overdose:
There is no established protocol for Rubraca overdose. Patients should seek medical attention immediately if an overdose is suspected.
Adverse reactions:
Common side effects of Rubraca include nausea, fatigue, vomiting, loss of appetite, abdominal pain, and constipation. It may also cause bone marrow suppression, anemia, and electrolyte abnormalities. Patients should inform their healthcare provider of any abnormal and persistent symptoms during treatment.
In conclusion, Rubraca is an orally administered medication belonging to the class of PARP inhibitors used to treat advanced ovarian cancer and prostate cancer. It inhibits the PARP enzyme, leading to the accumulation of DNA damage in cells that have already been damaged by chemotherapy, leading to cell death. Rubraca is taken orally with or without food, but dosage and duration may differ according to the patient’s condition. Special precautions should be taken as it may cause an increased risk of infection. Common side effects include nausea, fatigue, and loss of appetite. Rubraca should be stored at room temperature, away from light and moisture.
Reviews
There are no reviews yet.